Kalaris Therapeutics, Inc. 8-K

What Happened
Kalaris Therapeutics, Inc. announced on May 12, 2026 that it issued a press release reporting its financial results for the quarter ended March 31, 2026. The press release is furnished as Exhibit 99.1 to the Company’s Current Report on Form 8‑K. The filing states the information is being furnished (not “filed”) under the Exchange Act and is not subject to Section 18 liability or incorporated by reference into other filings unless explicitly stated.

Key Details

• Date of announcement: May 12, 2026.
• Reporting period: quarter ended March 31, 2026 (Q1 2026).
• Press release furnished as Exhibit 99.1 to the Form 8‑K.
• Cover Page Interactive Data File included as Exhibit 104; information furnished is not deemed “filed” under the Exchange Act.

Why It Matters
An 8‑K reporting quarterly results is the company’s official way to disclose recent earnings, revenue, cash position and other operating metrics that investors and analysts use to evaluate performance. This Form 8‑K indicates the company has publicly released its Q1 2026 results; investors should review the Exhibit 99.1 press release for the specific numbers (revenue, net loss/gain, cash runway, guidance) to assess impacts on valuation, cash needs, or near‑term financing plans.